Imeik Technology Development Co.,Ltd. (SHE:300896)
China · Delayed Price · Currency is CNY 91.40
-0.96 (-1.04%)
Aug 24, 2026, 3:04 PM CST
SHE:300896 Revenue
Imeik Technology Development had revenue of 581.98M CNY in the quarter ending June 30, 2026, a decrease of -8.45%. This brings the company's revenue in the last twelve months to 2.37B, down -11.20% year-over-year. In the year 2025, Imeik Technology Development had annual revenue of 2.45B, down -18.94%.
Revenue (ttm)
2.37B
Revenue Growth
-11.20%
P/S Ratio
11.63
Revenue / Employee
1.62M
Employees
1,458
Market Cap
27.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45B | -573.05M | -18.94% |
| Dec 31, 2024 | 3.03B | 156.32M | 5.45% |
| Dec 31, 2023 | 2.87B | 930.51M | 47.99% |
| Jan 1, 2023 | 1.94B | 490.97M | 33.91% |
| Jan 1, 2022 | 1.45B | 738.58M | 104.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Intco Medical Technology | 11.92B |
| Winner Medical | 11.14B |
| Tofflon Science and Technology Group | 5.20B |
| Zhende Medical | 4.34B |
| Gan & Lee Pharmaceuticals. | 3.95B |
| Micro-Tech (Nanjing) Co.,Ltd | 3.34B |
| iRay Group | 2.86B |
| Shenyang Xingqi Pharmaceutical | 2.62B |
Imeik Technology Development News
- 4 days ago - Imeik Technology Development Quarterly report: Q2 2026 - Filings
- 4 months ago - Imeik Technology Development Quarterly report: Q1 2026 - Filings
- 5 months ago - Imeik Technology Development Annual report: Q4 2025 - Filings
- 10 months ago - Imeik Technology Development Quarterly report: Q3 2025 - Filings